Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences, Inc. has launched the Pacira Innovation and Training Center of Tampa (PITT), aimed at enhancing clinician education in non-opioid pain management techniques. The facility features state-of-the-art technology, including ultrasound scanning stations and a large LCD presentation wall. Ongoing workshops will focus on iovera° training, promoting best practices in pain management. Pacira emphasizes the importance of training for improved patient outcomes, reflecting a commitment to shift procedures toward non-opioid solutions. This strategic initiative is expected to contribute to the growing field of regional anesthesia.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its third quarter financial results on October 29, 2020, before U.S. market opening. Following this, a live conference call and webcast will be held at 8:30 a.m. ET. Participants can join by dialing 1-877-845-0779 or 1-720-545-0035 (international), using passcode 5997369. Replay options will be available for one week. Pacira is known for its non-opioid pain management solutions, especially its long-acting analgesic, EXPAREL®, and the iovera⁰ cryoanalgesia device.

Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $113.7 million and iovera° at $2.7 million for Q3 2020. Sales for September were $39.5 million for EXPAREL and $1.1 million for iovera°. EXPAREL average daily sales exceeded prior year levels at 110% for September. The company is optimistic about future growth due to increased demand for EXPAREL in both elective and non-elective procedures. A new Innovation and Training Center in Tampa is set to enhance training for pain management techniques.

Pacira BioSciences (Nasdaq: PCRX) announced a positive opinion from the European Medicines Agency’s CHMP recommending marketing authorization for its pain management drug, EXPAREL, for postsurgical analgesia. This recommendation was supported by four pivotal studies highlighting EXPAREL's effectiveness in reducing pain scores and opioid use in various surgical settings. A final European Commission decision is expected in November 2020. This step aligns with Pacira's vision to lead in non-opioid pain management, with EXPAREL already utilized in over seven million patients in the U.S.

Pacira BioSciences (PCRX) and IPG have announced a partnership aimed at reducing postsurgical opioid prescriptions and lowering surgical costs across IPG's health plan network. The collaboration will see IPG reimbursing for EXPAREL®, a non-opioid pain management solution, to enhance surgical care quality and affordability. Both companies will create educational resources to optimize pain management practices, with Pacira emphasizing the benefits of non-opioid approaches for improved patient outcomes and satisfaction.

PARSIPPANY, N.J., Sept. 11, 2020 - Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 H.C. Wainwright 22^nd Annual Global Investment Conference on September 14, 2020, at 3:30 PM ET. Interested parties can listen to the live audio through the company’s website. A replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, with its flagship product, EXPAREL®, launched in April 2012. The firm advocates for reduced opioid reliance in healthcare.

Pacira BioSciences (PCRX) reported preliminary August 2020 net product sales of EXPAREL at $36.1 million, reflecting average daily sales at 111% of 2019 levels. The rise in sales is attributed to the growing adoption of EXPAREL among surgical centers and anesthesiologists, driven by a shift towards outpatient procedures as restrictions on elective surgeries ease amid COVID-19. The company aims to provide transparency by reporting monthly sales until full visibility on pandemic impacts is achieved. Financial data is preliminary and unaudited.

Pacira BioSciences (Nasdaq: PCRX) reported Q2 2020 revenues of $75.5 million, down 26% from $102.6 million in Q2 2019, largely due to the impacts of COVID-19. EXPAREL net sales were $73.0 million, also down by 26%. The company’s GAAP net loss reached $7.3 million ($0.17 per share), contrasting with a net income of $2.7 million in the same period last year. Total operating expenses decreased to $82.7 million. Pacira has seen a recovery in EXPAREL sales since April and aims to expand its non-opioid pain management solutions. The FDA accepted an sNDA for EXPAREL for pediatric use, with an expected decision by March 2021.

Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 AM ET. Interested parties can access the live audio via the company’s website. A webcast replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, including EXPAREL® and the iovera⁰ system.